S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

ViewRay Stock Forecast, Price & News

+0.27 (+3.78 %)
(As of 09/24/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.95 million shs
Average Volume1.57 million shs
Market Capitalization$1.22 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for ViewRay and its competitors with MarketBeat's FREE daily newsletter.

ViewRay logo

About ViewRay

ViewRay, Inc. designs, manufactures and markets magnetic resonance imaging (MRI) system. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova in 2004 and is headquartered in Oakwood Village, OH.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.03 out of 5 stars

Medical Sector

541st out of 1,351 stocks

Electromedical Equipment Industry

12th out of 31 stocks

Analyst Opinion: 1.4Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

ViewRay (NASDAQ:VRAY) Frequently Asked Questions

Is ViewRay a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ViewRay stock.
View analyst ratings for ViewRay
or view top-rated stocks.

What stocks does MarketBeat like better than ViewRay?

Wall Street analysts have given ViewRay a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ViewRay wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ViewRay's next earnings date?

ViewRay is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for ViewRay

How were ViewRay's earnings last quarter?

ViewRay, Inc. (NASDAQ:VRAY) released its earnings results on Thursday, August, 5th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.03. The business earned $15.03 million during the quarter, compared to the consensus estimate of $14.11 million. ViewRay had a negative net margin of 189.42% and a negative trailing twelve-month return on equity of 76.57%.
View ViewRay's earnings history

How has ViewRay's stock price been impacted by COVID-19?

ViewRay's stock was trading at $1.69 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, VRAY shares have increased by 338.5% and is now trading at $7.41.
View which stocks have been most impacted by COVID-19

What guidance has ViewRay issued on next quarter's earnings?

ViewRay issued an update on its FY 2021 earnings guidance on Thursday, September, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $63 million-$73 million, compared to the consensus revenue estimate of $73.15 million.

What price target have analysts set for VRAY?

5 equities research analysts have issued 1 year price targets for ViewRay's shares. Their forecasts range from $3.00 to $7.00. On average, they anticipate ViewRay's share price to reach $5.60 in the next year. This suggests that the stock has a possible downside of 24.4%.
View analysts' price targets for ViewRay
or view top-rated stocks among Wall Street analysts.

Who are ViewRay's key executives?

ViewRay's management team includes the following people:
  • Scott William Drake, President, Chief Executive Officer & Director
  • Zachary Stassen, Chief Financial Officer
  • James F. Dempsey, Chief Scientific Officer
  • Martin Fuss, Chief Medical Officer
  • Robert S. McCormack, Secretary, Senior VP & General Counsel

What is Scott Drake's approval rating as ViewRay's CEO?

5 employees have rated ViewRay CEO Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among ViewRay's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ViewRay own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

When did ViewRay IPO?

(VRAY) raised $52 million in an initial public offering (IPO) on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

What is ViewRay's stock symbol?

ViewRay trades on the NASDAQ under the ticker symbol "VRAY."

Who are ViewRay's major shareholders?

ViewRay's stock is owned by a variety of retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (14.38%), FMR LLC (14.07%), Fosun International Ltd (11.88%), BlackRock Inc. (5.84%), Vanguard Group Inc. (4.10%) and Bamco Inc. NY (2.31%). Company insiders that own ViewRay stock include International Ltd Fosun, Scott William Drake and Zachary William Stassen.
View institutional ownership trends for ViewRay

Which institutional investors are selling ViewRay stock?

VRAY stock was sold by a variety of institutional investors in the last quarter, including Fosun International Ltd, JPMorgan Chase & Co., Tamarack Advisers LP, State Street Corp, BlackRock Inc., Bank of America Corp DE, Millennium Management LLC, and Deutsche Bank AG.
View insider buying and selling activity for ViewRay
or view top insider-selling stocks.

Which institutional investors are buying ViewRay stock?

VRAY stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, Nuveen Asset Management LLC, Vanguard Group Inc., Balyasny Asset Management LLC, Bamco Inc. NY, Calamos Advisors LLC, Goldman Sachs Group Inc., and Point72 Asset Management L.P.. Company insiders that have bought ViewRay stock in the last two years include Scott William Drake, and Zachary William Stassen.
View insider buying and selling activity for ViewRay
or or view top insider-buying stocks.

How do I buy shares of ViewRay?

Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ViewRay's stock price today?

One share of VRAY stock can currently be purchased for approximately $7.41.

How much money does ViewRay make?

ViewRay has a market capitalization of $1.22 billion and generates $57.02 million in revenue each year. The company earns $-107,910,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis.

How many employees does ViewRay have?

ViewRay employs 236 workers across the globe.

What is ViewRay's official website?

The official website for ViewRay is www.viewray.com.

Where are ViewRay's headquarters?

ViewRay is headquartered at 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146.

How can I contact ViewRay?

ViewRay's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at (440) 703-3210 or via email at [email protected].

This page was last updated on 9/25/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.